公开(公告)号：US20240343716A1

公开(公告)日：2024-10-17

申请号：US18435619

申请日：2024-02-07

申请人： ABIVAX ,  CENTRE NATIONAL DE RECHERCHE SCIENTIFIQUE ,  INSTITUT CURIE ,  UNIVERSITE DE MONTPELLIER

发明人： Jamal TAZI ,  Florence MAHUTEAU ,  Pierre ROUX ,  Romain NAJMAN ,  Didier SCHERRER ,  Carsten BROCK ,  Nathalie CAHUZAC ,  Gilles GADEA ,  Noelie CAMPOS ,  Aude GARCEL ,  Julien SANTO

IPC分类号： C07D413/04 ,  A61K31/4709 ,  A61K31/4985 ,  C07D213/74 ,  C07D215/38 ,  C07D215/42 ,  C07D215/46 ,  C07D217/02 ,  C07D241/44 ,  C07D401/12 ,  C07D403/12

CPC分类号： C07D413/04 ,  A61K31/4709 ,  A61K31/4985 ,  C07D213/74 ,  C07D215/38 ,  C07D215/42 ,  C07D215/46 ,  C07D217/02 ,  C07D241/44 ,  C07D401/12 ,  C07D403/12

摘要： The manufacture and use of compounds of formula (Ia) or a pharmaceutically acceptable salt thereof for preventing, inhibiting or treating cancer, AIDS and/or premature aging. The compounds of formula (Ia) being:




where:



R independently represents a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —CN group, a hydroxyl group, a —COOR1 group, a (C1-C3)fluoroalkyl group, a —NO2 group, a —NR1R2 group, or a (C1-C3)alkoxy group;
R′ is a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —NO2 group, a (C1-C3)alkoxy group, or a —NR1R2 group; and
R1 and R2 are a hydrogen atom or a (C1-C3)alkyl group.

公开(公告)号：US20200172525A1

公开(公告)日：2020-06-04

申请号：US16787471

申请日：2020-02-11

申请人： ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT CURIE ,  UNIVERSITE DE MONTPELLIER

发明人： Jamal TAZI ,  Florence MAHUTEAU ,  Romain NAJMAN ,  Didier SCHERRER ,  Julien SANTO

IPC分类号： C07D413/04 ,  C07D215/38 ,  C07D241/44 ,  C07D401/12 ,  C07D403/12 ,  C07D217/02 ,  A61K31/4709 ,  A61K31/4985 ,  C07D213/74 ,  C07D215/42 ,  C07D215/46

摘要： The present disclosure is generally directed to the manufacture and use of compounds described herein for preventing, inhibiting or treating cancer, AIDS and/or premature aging, or the manufacture and use of a pharmaceutical composition comprising at least one of the compounds, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier for preventing, inhibiting or treating cancer, AIDS and/or premature aging.

公开(公告)号：US20180030078A1

公开(公告)日：2018-02-01

申请号：US15552587

申请日：2016-02-19

申请人： ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT CURIE ,  UNIVERSITE DE MONTPELLIER

发明人： Didier SCHERRER ,  Aude GARCEL ,  Noelie CAMPOS ,  Jamal TAZI ,  Audrey VAUTRIN ,  Florence MAHUTEAU ,  Romain NAJMAN ,  Pauline FORNARELLI

IPC分类号： C07H17/02

CPC分类号： C07H17/02 ,  C07D405/12

摘要： The present invention relates to a quinoline derivative of formula (1) or one of its pharmaceutically acceptable salts. The present invention further relates to said quinoline derivative for medicament and for use in the treatment or prevention of a viral or retroviral infection and in particular AIDS or an AIDS-related condition or Human Immunodeficiency virus (HIV). The present invention also relates to a pharmaceutical composition comprising said quinoline derivative and to the process for preparing it as to a novel intermediate compound.

公开(公告)号：US20170204063A1

公开(公告)日：2017-07-20

申请号：US15326755

申请日：2015-07-17

申请人： ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT CURIE ,  UNIVERSITE DE MONTPELLIER

发明人： Jamal TAZI ,  Romain NAJMAN ,  Florence MAHUTEAU ,  Didier SCHERRER ,  Karim CHEBLI ,  Michael HAHNE

IPC分类号： C07D215/38 ,  C07D401/12

CPC分类号： C07D215/38 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/5377 ,  C07D401/12 ,  C12Q1/6883 ,  C12Q2600/136 ,  C12Q2600/158 ,  C12Q2600/178 ,  G01N33/5023 ,  G01N33/5055

摘要： The present invention relates to a compound of formula (I) wherein: Formula (II) means an aromatic ring wherein V is C or N and when V is N; Q is N or O, provided that R″ does not exist when Q is O; R′ independently represent a hydrogen atom or a group chosen among a (C1-C3)alkyl group, a halogen atom, a hydroxy! group, a —COOR1 group, a —NO2 group, a —NR1R2 group, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (C1-C3)fluoroalkyl group, a —O—P(=O)—(OR3XOR4) group, a (C1-C4)alkoxy group and a —CN group, and can further be a group chosen among: (IIa), (IIIa) or anyone of its pharmaceutically acceptable salt, for use in the treatment and/or prevention of an inflammatory disease.

公开(公告)号：US20170197938A1

公开(公告)日：2017-07-13

申请号：US15326698

申请日：2015-07-17

申请人： ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT CURIE ,  UNIVERSITE DE MONTPELLIER

发明人： Jamal TAZI ,  Romain NAJMAN ,  Florence MAHUTEAU ,  Didier SCHERRER ,  Aude GARCEL ,  Noëlie CAMPOS

IPC分类号： C07D401/12

CPC分类号： C07D401/12

摘要： The present invention relates to a compound of formula (1) in the form of a base or addition salt with an acid, particularly a pharmaceutically acceptable acid. It further relates to a pharmaceutical composition including the compound and at least one pharmaceutically acceptable excipient, to a process for preparing said compound and to a corresponding intermediate compound.

公开(公告)号：US20240182422A1

公开(公告)日：2024-06-06

申请号：US18284253

申请日：2022-03-23

申请人： ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  UNIVERSITE DE MONTPELLIER ,  INSTITUT CURIE

发明人： Jérôme DENIS ,  Fabien DE BLASIO ,  Thierry BOYER ,  Charles GUERIN ,  Julien MICHAUX ,  Romain NAJMAN ,  Florence MAHUTEAU-BETZER

IPC分类号： C07D215/38

CPC分类号： C07D215/38

摘要： A method for preparing a compound of formula (I), a powder, and a pharmaceutical composition are disclosed. The method includes: (i) reacting a compound of formula (II) with a compound of formula (III), to form the hydrochloride salt of the compound of formula (I), and (ii) recovering the compound of formula (I) in the form of a free base through addition of a base. In step (i), the molar ratio of the compound of formula (II) to the compound of formula (III) is in a range of from 1.00:0.80 to 1.00:1.20, and no metal catalyst is present. A powder including the composition of formula (I) may be obtained by the method. The powder may have a particle size distribution with specific D50, D90 and/or D10 values. A pharmaceutical composition may include the powder and at least one pharmaceutically acceptable excipient.

公开(公告)号：US20210087145A1

公开(公告)日：2021-03-25

申请号：US17113369

申请日：2020-12-07

申请人： ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT CURIE ,  UNIVERSITE DE MONTPELLIER

发明人： Jamal TAZI ,  Romain NAJMAN ,  Florence MAHUTEAU ,  Didier SCHERRER ,  Karim CHEBLI ,  Michael HAHNE

IPC分类号： C07D215/38 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/5377 ,  C12Q1/6883 ,  G01N33/50 ,  C07D401/12

摘要： The present disclosure relates to the use of a compound of formula (I) or anyone of its pharmaceutically acceptable salts, in the treatment and/or prevention of an inflammatory disease; wherein: means an aromatic ring wherein V is C or N and when V is N; Q is N or O, provided that R″ does not exist when Q is O; R′ independently represent a hydrogen atom or a group chosen among a (C1-C3)alkyl group, a halogen atom, a hydroxyl group, a —COOR1 group, a —NO2 group, a —NR1R2 group, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (C1-C3)fluoroalkyl group, a —O—P(═O)—(OR3)(OR4) group, a (C1-C4)alkoxy group and a —CN group, and can further be a group chosen among:

公开(公告)号：US20180339981A1

公开(公告)日：2018-11-29

申请号：US16050551

申请日：2018-07-31

申请人： ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT CURIE ,  UNIVERSITE DE MONTPELLIER

发明人： Jamal TAZI ,  Florence MAHUTEAU ,  Romain NAJMAN ,  Didier SCHERRER ,  Julien SANTO

IPC分类号： C07D413/04 ,  C07D215/46 ,  C07D215/42 ,  C07D213/74 ,  A61K31/4985 ,  A61K31/4709 ,  C07D403/12 ,  C07D401/12 ,  C07D241/44 ,  C07D215/38 ,  C07D217/02

摘要： The manufacture and use of compounds of formula (Ia) or a pharmaceutically acceptable salt thereof for preventing, inhibiting or treating cancer, AIDS and/or premature aging. The compounds of formula (Ia) being: where: R independently represents a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —CN group, a hydroxyl group, a —COOR1 group, a (C1-C3)fluoroalkyl group, a —NO2 group, a —NR1R2 group, or a (C1-C3)alkoxy group; R′ is a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —NO2 group, a (C1-C3)alkoxy group, or a —NR1R2 group; and R1 and R2 are a hydrogen atom or a (C1-C3) alkyl group.

公开(公告)号：US20180127353A1

公开(公告)日：2018-05-10

申请号：US15840847

申请日：2017-12-13

申请人： ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT CURIE ,  UNIVERSITE DE MONTPELLIER

发明人： Didier SCHERRER ,  Jamal TAZI ,  Romain NAJMAN ,  Florence MAHUTEAU ,  Pierre ROUX

IPC分类号： C07C237/30 ,  C07D233/61 ,  C07D401/12 ,  C07D249/06 ,  C07D233/64 ,  C07D213/36 ,  A61K31/5377 ,  A61K31/496 ,  A61K31/495 ,  A61K31/4545 ,  A61K31/4439 ,  A61K31/4409 ,  A61K31/4192 ,  A61K31/417 ,  A61K31/4164 ,  A61K31/167 ,  A61K31/166 ,  C07D213/38

CPC分类号： C07C237/30 ,  A61K31/166 ,  A61K31/167 ,  A61K31/4164 ,  A61K31/417 ,  A61K31/4192 ,  A61K31/4409 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/495 ,  A61K31/496 ,  A61K31/5377 ,  C07D213/36 ,  C07D213/38 ,  C07D233/61 ,  C07D233/64 ,  C07D249/06 ,  C07D401/12

摘要： The present disclosure relates to compound (I) wherein R1 and R2 independently represent a hydrogen atom, a (C1-C4)alkoxy group, a fluoro(C1-C4)alkoxy group, a hydroxyl group, a benzyloxy group, a di(C1-C4)alkylamino group, a pyridyl-vinyl group, a pyrimidinyl-vinyl group, a styryl group, or a —NHCOphenyl group; R3, R4 and R5 independently represent a hydrogen atom, a (C1-C4)alkyl group, a CONHR6 group, a —CONR7R8 group, a —SO2NHR6 group, or a heteroaryl group optionally substituted by a halogen atom, a —(CH2)nNR7R8 group or a hydroxy(C1-C4)alkyl group; R6 represents a hydrogen atom, a —(CHR9)m(CH2)nNR7R8 group or a (C1-C6)alkyl group optionally substituted by a hydroxyl group; or anyone of its pharmaceutically acceptable salt, for use in a method for preventing, inhibiting or treating a disease in a patient suffering thereof, said disease involving a deregulated p53. Some of said compounds are new and also form part of the disclosure.

公开(公告)号：US20170226095A1

公开(公告)日：2017-08-10

申请号：US15486836

申请日：2017-04-13

申请人： ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT CURIE ,  UNIVERSITE DE MONTPELLIER

发明人： Jamal TAZI ,  Florence MAHUTEAU ,  Pierre ROUX ,  Romain NAJMAN ,  Didier SCHERRER ,  Carsten BROCK ,  Nathalie CAHUZAC ,  Gilles GADEA ,  Noelie CAMPOS ,  Aude GARCEL ,  Julien SANTO

IPC分类号： C07D413/04 ,  C07D217/02 ,  C07D401/12 ,  C07D403/12 ,  C07D215/38 ,  C07D241/44

CPC分类号： C07D413/04 ,  A61K31/4709 ,  A61K31/4985 ,  C07D213/74 ,  C07D215/38 ,  C07D215/42 ,  C07D215/46 ,  C07D217/02 ,  C07D241/44 ,  C07D401/12 ,  C07D403/12

摘要： The manufacture and use of compounds of formula (Ia) or a pharmaceutically acceptable salt thereof for preventing, inhibiting or treating cancer, AIDS and/or premature aging. The compounds of formula (Ia) being: where: R independently represents a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —CN group, a hydroxyl group, a —COOR1 group, a (C1-C3)fluoroalkyl group, a —NO2 group, a —NR1R2 group, or a (C1-C3)alkoxy group; R′ is a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —NO2 group, a (C1-C3)alkoxy group, or a —NR1R2 group; and R1 and R2 are a hydrogen atom or a (C1-C3) alkyl group.